Business Wire

Kinaxis Appoints Razat Gaurav as New CEO

Share

Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced the appointment of Razat Gaurav as Chief Executive Officer (CEO) effective January 12, 2026, his official start date, at which time he will also join the Kinaxis Board of Directors.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108330975/en/

Razat Gaurav, Kinaxis CEO

“After a rigorous search, the Board selected Razat to lead the company as CEO,” said Bob Courteau, Interim CEO and Board Chair at Kinaxis. “Razat’s twenty-five years of experience in supply chain solutions, his proven track record in advancing innovation-driven growth, and his passion for developing high-performing cultures make him uniquely qualified for this role. The Board looks forward to supporting Razat as he leads Kinaxis to the next phase of growth and success.”

Gaurav has an established track record of building and scaling global organizations in high-growth markets. He was the former CEO of both Planview and LLamasoft and previously held senior roles at Blue Yonder and i2 Technologies. He is also a board member at SPS Commerce, a publicly traded SaaS company helping businesses exchange data, automate processes, and run more efficient supply chains.

Since becoming CEO of Planview in 2021, Gaurav transformed the company’s AI journey, anchoring its mission to build the digital future of connected work. Under his leadership, Planview launched an enterprise-grade next-generation AI platform designed to harness the power of the latest emerging data architectures and multi-agent AI capabilities. This led to Planview more than doubling its revenue while maintaining high operating margins during his tenure.

"I’m excited to join the Kinaxis team and return to my roots in supply chain,” said Razat Gaurav, Chief Executive Officer. “Kinaxis is uniquely positioned to redefine the future of intelligent supply chains. Building on its rich legacy of concurrent planning, I will champion the next generation of AI-driven decision making and supply chain orchestration, using the Maestro platform. I appreciate the Board’s confidence and pledge to lead the company in setting new standards for innovation, building lasting partnerships and creating value for employees, customers and shareholders.”

This planned leadership transition reinforces Kinaxis’s commitment to creating sustainable long-term value for employees, customers, and shareholders. With this appointment, and other key leadership additions including Mark Morgan, President of Global Commercial, the executive team at Kinaxis is built to deliver sustained growth and lead the transformation of global supply chains.

Bob Courteau, Interim CEO, will now return to his role as non-executive Board Chair of Kinaxis. Given Courteau’s recent tenure in an executive role, Angel Mendez will continue as Independent Lead Director.

About Kinaxis

Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains, and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that provide full transparency and agility across the entire supply chain — from multi-year strategic planning to last-mile delivery. We are trusted by renowned global brands to provide the agility and predictability needed to navigate today’s volatility and disruption. For more news and information, please visit kinaxis.com or follow us on LinkedIn.

Cautionary Note and Forward-Looking Information

This news release contains forward-looking information within the meaning of Canadian securities legislation. Forward-looking information relates to future events or anticipated performance. This information is provided to help readers understand management’s beliefs, expectations, and opinions as at the date of this release and may not be suitable for other purposes. Forward-looking information in this news release includes statements regarding Kinaxis’ plans and prospects for growth, expansion, and innovation. Kinaxis’ actual performance may be materially different.

Forward-looking information is subject to a variety of risks and uncertainties which could cause actual events or results to differ including, without limitation, the risks described under the heading “Risk Factors” in the Company’s annual information form dated February 26, 2025 for its fiscal year ended December 31, 2024 and other risks identified in the Company’s filings with Canadian securities regulators available on SEDAR+ at https://www.sedarplus.ca. These risk factors are not exhaustive. The Company does not assume any obligation to update forward-looking information, other than as required by applicable law. For the reasons set forth above, one should not place undue reliance on forward-looking information.

Source: Kinaxis Inc

View source version on businesswire.com: https://www.businesswire.com/news/home/20260108330975/en/

Contacts

Media Relations
Matt Tatham | Kinaxis
mtatham@kinaxis.com
+1 917-446-7227

Investor Relations
Rick Wadsworth | Kinaxis
rwadsworth@kinaxis.com
+1 613-907-7613

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release

MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of

FieldBee Vision wins Gold for Digital Technology Innovation at LAMMA 20269.1.2026 06:25:00 EET | Press release

FieldBee, the European leader in high-quality, easy-to-use and affordable precision agriculture technologies, proudly announces that FieldBee Vision has earned global recognition, becoming the Gold Winner in the Digital Technology Innovation of the Year category at the LAMMA Innovation Awards 2026. Lamma Show is the UK’s premier agricultural machinery, technology and equipment innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107606411/en/ FieldBee wins the LAMMA Innovation Award 2026 for Digital Technology Innovation of the Year for the FieldBee Vision (VisionSteer & VisionPro) system FieldBee Vision is part of the newly launched myFieldBee ecosystem, built to unify FieldBee’s precision farming tools and designed to connect navigation, autosteering, ISOBUS into one unified platform that supports planning, execution, monitoring and reporting. FieldBee Vision, the first modular retrofit agricultural vision system,

Survey Finds Over 70% of Chinese Doctors Recommend “AI Doctor Services” Like Ant Group’s AQ for Everyday Health Needs9.1.2026 05:31:00 EET | Press release

A recent survey by Life Times, a well-known Chinese public health media outlet, shows that AI doctor services are broadly supported by doctors in China. Among 500 physicians from the country’s top-tier (tertiary) hospitals, more than 70% said they would recommend AI doctor services to patients for everyday health questions and routine health management. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108456917/en/ Ant Group’s AI-native health app AQ is designed to address common, everyday health concerns and support healthy habit formation. Ant Group’s AQ was the most frequently recommended platform in the survey. The latest figures show that, as of January 2026, the app had accumulated 30 million monthly active users and answers over 10 million health-related questions daily, making it China’s leading AI-native health app. AQ—known in Chinese as Ant A-Fu—is an AI-native health app launched by Ant Group in June 2025. Desig

OPPO Joins VVC Advance Patent Pool as a Licensee and Extends HEVC Advance License9.1.2026 04:00:00 EET | Press release

Access Advance LLC and Guangdong OPPO Mobile Telecommunications Corp., Ltd. (OPPO) today announced that OPPO has joined the VVC Advance Patent Pool as a Licensee and renewed its HEVC Advance License. OPPO, one of the world's largest smartphone manufacturers with operations in more than 70 countries, has been a valued participant in Access Advance's HEVC patent pool since 2020, and more recently joined the Advance Video Distribution Patent (VDP) Pool as a Licensor. These latest agreements mark a new milestone in a broad and deepening relationship between the two companies, with OPPO now participating across all three of Access Advance's video codec licensing programs. The VVC Advance Patent Pool licenses patents essential to the VVC/H.266 standard, which delivers remarkable improvement of video compression performance over HEVC, enabling higher-quality video experiences including 4K, 8K, and HDR content with faster downloads and lower latency. The pool currently includes over 4,500 worl

Cessna Citation CJ3 Gen2 Enters Into Service, Delivering the Most Significant Gen2 Updates to Date8.1.2026 23:30:00 EET | Press release

The Cessna Citation CJ3 Gen2 has entered into service, setting a new standard for the Citation Gen2 family. Launch customers and longtime Citation owners Dave Mecartney and Shannon Day took delivery of their new aircraft this week. Mecartney—an experienced aviator with nearly two decades flying Citation light jets and a member of Textron Aviation’s Customer Advisory Board—helped shape the enhancements that elevate the CJ3 Gen2 experience. Key upgrades include Garmin autothrottle technology, added pilot legroom and a fully customizable cabin environment, all driven by customer feedback. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108455097/en/ Cessna Citation CJ3 Gen2 enters into service, delivering the most significant Gen2 updates to date (Photo credit: Textron Aviation). The Cessna Citation CJ3 Gen2 is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company. “The Citation CJ3 Gen2 deliv

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye